| 市场指数 | | | | --- | --- | --- | | 指数名称 | 收盘价 | 涨跌% | | 上证综指 | 3342.00 | (0.30) | | 深证成指 | 10126.83 | (0.69) | | 沪深 300 | 3846.16 | (0.17) | | 中小 100 | 6294.71 | (0.62) | | 创业板指 | 2011.77 | (0.87) | 证券研究报告——晨会聚焦 2025 年 5 月 12 日 | 5 月金股组合 | | | --- | --- | | 股票代码 | 股票名称 | | 002352.SZ | 顺丰控股 | | 1519.HK | 极兔速递-W | | 603181.SH | 皇马科技 | | 300014.SZ | 亿纬锂能 | | 688198.SH | 佰仁医疗 | | 000524.SZ | 岭南控股 | | 600519.SH | 贵州茅台 | | 9660.HK | 地平线机器人-W | | 688519.SH | 南亚新材 | | 301236.SZ | 软通动力 | 中银晨会聚焦-20250512 ■重点关注 【医药生物】 ...

Group 1: Company Performance - In 2024, the company achieved a revenue of 8.978 billion yuan, a year-on-year increase of 9.69%, and a net profit attributable to shareholders of 0.695 billion yuan, up 19.81% [1] - In Q1 2025, the company continued its high growth trend, with revenue and net profit attributable to shareholders increasing by 36.47% and 36.26% year-on-year, respectively [1] - The chairman emphasized the importance of product quality and consumer insights in achieving sustainable value for the company [1] Group 2: All Cotton Era's Growth - All Cotton Era, a subsidiary, achieved a revenue of 4.99 billion yuan in 2024, reflecting a year-on-year growth of 17.1% [2] - The core product, cotton soft towel, led the growth with a revenue of 1.56 billion yuan, up 31.2% year-on-year [2] - The company is expanding its product matrix with new offerings tailored to diverse consumer needs, emphasizing safety and environmental sustainability [2] Group 3: Sanitary Napkin Market Potential - The sanitary napkin market in China exceeds 100 billion yuan, with the company's sanitary napkin revenue reaching 0.7 billion yuan in 2024, a growth of 18.0% [3] - The company’s brand, Princess Nais, has seen increased recognition, indicating significant growth potential in market share [3] - The company employs a differentiated strategy with its sanitary napkin products, focusing on high-quality materials and safety [3] Group 4: Channel Expansion - The company diversified its online and offline channels, achieving online revenue of 3.07 billion yuan, a year-on-year increase of 18.9% [3] - The offline channel revenue grew by 33.4%, with 92 new stores opened, bringing the total to 487 by the end of 2024 [3] - The company aims for steady expansion with a focus on high-quality, profitable stores rather than merely increasing scale [3] Group 5: Medical Sector Recovery - The medical sector has stabilized and returned to normal growth in 2024, driven by new healthcare reforms and increasing demand [5] - The company is pursuing an "internal growth and external acquisition" strategy to enhance competitiveness, launching innovative products like cotton masks [5][6] - The company is expanding its market presence through partnerships and acquisitions, including a notable acquisition of GRI in the U.S. to strengthen local production capabilities [6]

圣湘生物：拟以1亿元增资圣维鲲腾 5月9日，圣湘生物（688289）发布公告称，公司计划以自有资金1亿元增资控股子公司湖南圣维鲲腾生 物科技有限公司（圣维鲲腾），用于完善公司在POCT（即时检验）领域的产业链布局。此次增资完成 后，圣湘生物将持有圣维鲲腾44.6441%的股权。此外，圣维鲲腾还将引入公司关联方长沙圣维荣泉创 业投资有限公司作为新投资者，投资1亿元，本次交易构成关联交易。 资料显示，圣湘生物成立于2008年4月，主营业务为以自主创新基因技术为核心，集诊断试剂和仪器的 研发、生产、销售，以及第三方医学检验服务于一体的体外诊断整体解决方案。 所属行业：医药生物–医疗器械–体外诊断 亚光科技：控股子公司签订1.01亿元备产协议 5月9日，亚光科技（300123）发布公告称，公司控股子公司成都亚光于近日收到与特殊机构客户签订的 《产品预估备产协议书》，预估总额1.01亿元，占公司最近一个会计年度经审计的营业收入的10.56%。 协议标的为科研生产任务器材。 资料显示，亚光科技成立于2003年6月，主营业务是高性能微波电子、航海装备及其产品的研发设计与 制造。 所属行业：国防军工–军工电子Ⅱ–军工电子Ⅲ ...

Group 1: Company Performance and Market Opportunities - The company reported significant growth in the sanitary napkin segment, with a market size in China exceeding 100 billion RMB, indicating vast growth potential despite being a relatively small player [5] - The aging population and increasing health management needs are driving demand for medical supplies, creating a larger market space for the company [2] - The company aims to enhance its market competitiveness by focusing on disposable medical supplies through acquisitions and expanding its product categories [2] Group 2: Strategic Initiatives - The company is committed to providing integrated solutions for hospitals, pharmacies, and home care, addressing pain points in quality, supply chain, and digital integration [2] - Continuous investment in R&D is prioritized to innovate products that fill market gaps and meet patient and healthcare institution needs [2] - The company is advancing smart manufacturing and AI technology applications to improve production efficiency and reduce costs [2] Group 3: Channel Strategy and Growth Projections - The medical segment's channel strategy includes overseas business, domestic hospital lines, consumer medical business, and cross-border e-commerce, with a focus on significant growth in domestic hospital lines in 2025 [9][10] - The overseas business is primarily focused on Europe, while the domestic hospital segment is being segmented into traditional dressings, surgical materials, and high-end dressings [9] - The cross-border e-commerce channel has been the fastest-growing, particularly on platforms like Amazon, despite potential impacts from current tariff policies [10] Group 4: Impact of Tariff Policies - The company anticipates limited impact from U.S. tariff policies, with affected sales in overseas divisions and cross-border e-commerce remaining in single-digit percentages of the medical segment [6][7] - Strategies to mitigate tariff impacts include increasing investments in South America and expanding existing U.S. operations [6][7] - The company maintains strong competitive advantages in the U.S. market for medical supplies, with various strategies to manage tariff-related challenges [7] Group 5: Brand Management and Investor Relations - The company has implemented a market value management system to protect and return value to investors, with regular monitoring against industry benchmarks [11] - A rising trend in dividend payouts has been established, with plans for mid-year dividends starting in 2024 [11] - The company emphasizes transparency and communication with investors, enhancing information disclosure and hosting performance briefings [11] Group 6: Product Development and Consumer Engagement - The company is focusing on product innovation in the sanitary napkin sector, utilizing high-quality cotton and advanced technologies to enhance user experience [5] - Initiatives to improve consumer trust include product traceability through QR codes and real-time factory monitoring [14][15] - The company is actively engaging with consumers for feedback on product improvements, integrating suggestions into new product developments [14]

金融界5月8日消息，上证指数低开高走，中证全指医疗保健设备与服务指数 (医疗保健，H30178)上涨 0.39%，报13367.74点，成交额146.35亿元。 数据统计显示，中证全指医疗保健设备与服务指数近一个月上涨5.82%，近三个月下跌2.05%，年至今 下跌2.72%。 据了解，中证全指医疗保健设备与服务指数从中证全指指数中选取与医疗保健主题相对应的行业内上市 公司证券作为指数样本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以 1000.0点为基点。 从指数持仓来看，中证全指医疗保健设备与服务指数十大权重分别为：迈瑞医疗（9.57%）、爱尔眼科 （8.34%）、联影医疗（7.63%）、爱美客（3.55%）、惠泰医疗（3.28%）、鱼跃医疗（2.88%）、新产 业（2.81%）、美年健康（2.35%）、乐普医疗（2.07%）、九安医疗（2.03%）。 从中证全指医疗保健设备与服务指数持仓的市场板块来看，深圳证券交易所占比60.66%、上海证券交 易所占比39.34%。 从中证全指医疗保健设备与服务指数持仓样本的行业来看，医疗设备占比34.34%、医疗耗材占比 27.26% ...

达实智能：签约5812.89万元智慧医院项目 5月8日晚，达实智能（002421）发布公告称，公司与蚌埠医学院第一附属医院及蚌埠城建投资发展有限 公司签署合同，中标浙江大学医学院附属第二医院安徽医院（肿瘤）项目智能化项目，合同金额为 5812.89万元。该项目旨在打造集医疗、科研、教学、预防保健及康复为一体的三级甲等肿瘤专科医 院，项目顺利实施后将对公司未来业绩产生积极影响。 资料显示，达实智能成立于1995年3月，主营业务是基于自主研发的AIoT智能物联网管控平台，聚合模 块化的空间场景应用，为用户提供全生命周期的智慧服务。 所属行业：计算机–IT服务Ⅱ–IT服务Ⅲ 华虹公司：一季度净利润2276.34万元 同比下降89.73% 5月8日晚，华虹公司（688347）发布2025年第一季度报告，公司2025年第一季度实现营业收入39.13亿 元，同比增长18.66%；实现归属于上市公司股东的净利润2276.34万元，同比下降89.73%；基本每股收 益为0.01元/股。 资料显示，华虹公司成立于2005年1月，主营业务是开发与应用嵌入式/独立式非易失性存储器、功率器 件、模拟及电源管理和逻辑及射频等'8英寸+ ...

金融界5月8日消息，上证指数低开高走，上证科创板医疗指数 (科创医疗，950255)报725.07点。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在 下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将 其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 数据统计显示，上证科创板医疗指数近一个月上涨4.40%，近三个月上涨0.19%，年至今下跌0.01%。 来源：金融界 据了解，上证科创板医疗指数从科创板中选取不超过30家医疗领域的上市公司证券作为指数样本，以反 映科创板中医疗上市公司证券的整体表现。该指数以2022年12月30日为基日，以1000.0点为基点。 从指数持仓来看，上证科创板医疗指数十大权重分别为：惠泰医疗（11.76%）、联影医疗 （10.54%）、爱博医疗（7.72%）、奕瑞科技（6.34%）、圣湘生物（5.03%）、南微医学（5.02%）、 心脉医疗（4.57%）、海尔生物（4 ...

5、请问贵公司医疗器械方面与欧洲是否有进一步的合作。 回复：尊敬的投资者，您好！2024 年 10 月，公司董事长携医 疗团队赴瑞士与某 IVD 客户进行友好洽谈，就未来两年双方深 入合作开发的产品计划进行了深入沟通。初步就该客户推出的 全球十余款新品系列达成开发意向，并签署相关协议，其中部 分产品已取得相应订单。2025 年第一季度，该 IVD 客户贡献 营收较上年同期增长 90%左右，同时正在进一步讨论扩大未来 合作的渠道、领域及产品覆盖区域！敬请广大投资者注意投资 风险，感谢您对公司的关注！ 6、半导体耗材领域，是否已经在供货阶段？能对公司实质业 绩提供多大的支撑？贵司题材概念为何没有半导体？ 证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2025-001 | | □分析师会议 □媒体采访 □√ 业绩说明会 | □特定对象调研 | | --- | --- | --- | | 投资者关系活 | | | | | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | □其他 | | ...

Core Points - The China Securities Index for Hong Kong Stock Connect Medical Comprehensive Index reported a value of 1467.39 points, showing a monthly increase of 0.37%, a three-month increase of 10.32%, and a year-to-date increase of 11.90% [1] - The index is designed to reflect the overall performance of different industry securities within the Hong Kong Stock Connect, categorized according to the China Securities Industry Classification Standard [1] - The top ten weighted stocks in the index include JD Health (15.7%), Alibaba Health (15.39%), Sinopharm (11.5%), Weigao Group (7.35%), MicroPort Medical (4.9%), Ping An Good Doctor (4.63%), Shanghai Pharmaceuticals (3.7%), MicroPort Scientific-B (3.6%), Xianjian Technology (3.16%), and Jinxin Fertility (3.03%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.51%, medical services for 23.49%, medical consumables for 23.03%, medical devices for 3.98%, and in vitro diagnostics for 0.98% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments in case of special events affecting the index sample [2]

金融界4月29日消息，上证指数低开震荡，上证科创板医疗指数 (科创医疗，950255)报697.45点。 从上证科创板医疗指数持仓的市场板块来看，上海证券交易所占比100.00%。 从上证科创板医疗指数持仓样本的行业来看，医疗耗材占比47.05%、医疗设备占比31.91%、体外诊断 占比21.04%。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在 下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将 其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 来源：金融界 数据统计显示，上证科创板医疗指数近一个月下跌6.84%，近三个月下跌2.25%，年至今下跌3.82%。 据了解，上证科创板医疗指数从科创板中选取不超过30家医疗领域的上市公司证券作为指数样本，以反 映科创板中医疗上市公司证券的整体表现。该指数以2022年12月30日为基日，以1000.0点为基点。 从指数持仓来看，上证科创板医疗指数十大 ...